BerandaBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Tutup sebelumnya
$67,38
Rentang hari
$65,95 - $67,58
Rentang tahun
$61,15 - $94,85
Kapitalisasi pasar
12,70Â M USD
Volume Rata-Rata
1,35Â jt
Rasio P/E
40,04
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 745,74Â jt | 28,28% |
Biaya operasional | 443,39Â jt | 4,88% |
Laba bersih | 106,08Â jt | 162,72% |
Margin laba bersih | 14,22 | 104,60% |
Penghasilan per saham | 0,91 | 97,83% |
EBITDA | 132,90Â jt | 136,43% |
Tarif pajak efektif | 21,10% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 930,44Â jt | -17,36% |
Total aset | 6,85Â M | 1,38% |
Total liabilitas | 1,44Â M | -22,75% |
Total ekuitas | 5,41 M | — |
Saham yang beredar | 190,58 jt | — |
Harga terhadap nilai buku | 2,37 | — |
Tingkat pengembalian aset | 4,09% | — |
Tingkat pengembalian modal | 4,59% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 106,08Â jt | 162,72% |
Kas dari operasi | 221,48Â jt | 63,28% |
Kas dari investasi | -16,16Â jt | 64,72% |
Kas dari pembiayaan | -499,12Â jt | -63.240,74% |
Perubahan kas bersih | -296,70Â jt | -425,93% |
Arus kas bebas | 165,57Â jt | 86,81% |
Tentang
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Didirikan
Mar 1997
Kantor pusat
Situs
Karyawan
3.401
